Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGY 2: INZ-701 in Infants With ENPP1 Deficiency
NCT07473973Phase 3Terminated
- Sponsor
- Inozyme Pharma
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 3 trial of INZ-701 in ENPP1 deficiency, sponsored by Inozyme Pharma. Started Mar 2025; status: terminated.
02
Drugs
INZ-701
03
Conditions
ENPP1 deficiency
Beyond the preview
Go deeper on NCT07473973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473973.